Brilliant Violet 785™ anti-mouse CD3ε Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Armenian Hamster

Immunogen

H-2K^b-specific mouse cytotoxic T lymphocyte clone BM10-37

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis¹, as well as T cell activation assays, inducing proliferation and cytokine production^1,2,7,12,16. It also induces apoptosis in immature thymocytes³²,  and in vivo T cell depletion^8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation¹, immunohistochemical staining^14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting⁴, complement-mediated cytotoxicity⁶, in vitro and in vivo stimulation of T cells^1,2,7,12,16, immunofluorescent staining⁵, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells¹¹. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)

Product Citations

1. Jiang W, et al. 2021. Sci Rep. 11:1864. PubMed
2. Bettke JA, et al. 2022. Infect Immun. 90:e0007022. PubMed
3. Lees-Shepard JB, et al. 2022. J Clin Invest. 132: . PubMed
4. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
5. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
6. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
7. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
8. Diao L, et al. 2022. iScience. 25:105511. PubMed
9. Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed
10. Pingili AK, et al. 2021. Cell Reports. 35(12):109285. PubMed
11. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
12. Chan YK, et al. 2021. Sci Transl Med. 13:. PubMed
13. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
14. Medler TR et al. 2018. Cancer cell. 34(4):561-578 . PubMed
15. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
16. Liu Y, et al. 2019. Nat Commun. 10:324. PubMed
17. Lu X, et al. 2019. Circ Res. 125:1055. PubMed
18. Somogyi E, et al. 2021. Front Genet. 12:684152. PubMed
19. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
20. Xia L, et al. 2021. Cell Chemical Biology. 28(5):610-624.e5. PubMed

RRID

AB_2565969 (BioLegend Cat. No. 100355)

Antigen Details

Structure

Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD

Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function

TCR signal transduction, T cell activation, antigen recognition

Ligand/Receptor

Peptide antigen/MHC-complex

Cell Type

NKT cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules, TCRs

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID

12501 View all products for this Gene ID

UniProt

View information about CD3epsilon on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats